Oncology

Genetic ancestry was linked to differences in colorectal cancer (CRC) burden and age-specific risk, with implications for screening.

It also flagged persistent gaps in biomarker testing and the limits of cross-trial comparisons for treatment selection.

July AJMC author Anuraag R. Kansal, PhD, explains how metastatic cancer diagnoses drive Medicaid spending and why earlier screening could lower costs.

All from July, these 5 novel therapeutics each claimed a “first” in their category.

Phase 3 SOLARIS found high-dose vitamin D3 added to standard chemotherapy did not significantly improve progression-free survival in metastatic CRC.

OpenEvidence plugs into OneOncology tools, delivering fast oncology evidence, genomic context and clinical-trial matches at the point of care.

Peter Forsberg, MD, discusses referral pathways, payer barriers, and expanding access to CAR T-cell and bispecific therapies.

Novartis says it can deliver doses to treatment sites with 5 days of order.

Panelists emphasized coordinated care, biomarker testing, innovative therapies, and clinical trial access to advance precision oncology.

New data suggest acalabrutinib appears to reduce the target that macrophages are supposed to recognize in patients with CLL.

An unanswered question: will an additional 7 minutes translate into fewer postcolonoscopy cancers and lower downstream costs?

These findings reinforce that matching therapy intensity and type to genetic and treatment-history profile is likely to be the next lever for improving outcomes.

A study found that elevated IL-6 and IL-17A levels were associated with greater fatigue for up to 3 years after CRC diagnosis.

Panel experts at Nashville’s IVBM event discussed matching cancer therapy intensity to disease, easing access barriers, and reforming pharmacy/PBM policies.

A July AJMC study found metastatic cancer diagnoses significantly increase Medicaid spending, highlighting the potential budget benefits of earlier detection.

Experts discussed biomarker testing, novel cancer therapies, multidisciplinary care, and strategies to expand access.

Navista names Jeff Hunnicutt COO, bringing in a well-known oncology leader with experience in technology and innovation at the practice level.

Integrated specialty pharmacies have EHR access, faster prior authorizations, and built-in monitoring, Brooke Looney, PharmD, CSP, highlighted.

Benjamin Garmezy, MD, explains what varying Nectin-4 expression means for treatment selection in bladder cancer and what trials are still needed.

Clinical trial access remains the biggest barrier in sarcoma care, with travel and insurance limits keeping patients from open studies, says Vicki Keedy, MD.

Justin Balko, PharmD, PhD, explains why residual disease in triple-negative breast cancer signals a biology gap, and what ADC trials and cell-free DNA monitoring may reveal.

FDA approves zidesamtinib for ROS1-positive NSCLC after prior TKIs, offering a new option for resistant and CNS-active disease.

Subcutaneous checkpoint inhibitors drove up volume and forced staffing changes, according to Angie Maynard, PharmD, MS, BCOP, and bispecifics will bring another shift.

AI-guided breast screening is advancing faster than coverage policy, guidelines, and imaging capacity—raising questions about who qualifies and who pays.

CRC treatment delays were linked to higher metastatic risk, but meaningful thresholds varied by treatment pathway, supporting tailored benchmarks.